Pharmaceutical

Roche to leverage Dyno Therapeutics tech for novel gene therapies in neuro disorders

With the formation of a new strategic partnership, Dyno Therapeutics is responsible for the development of novel AAV capsids.

Nov 1, 2024 - 04:00
Roche to leverage Dyno Therapeutics tech for novel gene therapies in neuro disorders
With the formation of a new strategic partnership, Dyno Therapeutics is responsible for the development of novel AAV capsids.
Read the original article

Tags:

Previous Article

Psoriasis biosimilars and pricing changes herald treatment paradigm disruptions

Next Article

Bladder cancer diagnoses to top 300,000 in major markets by 2033

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Opinion: The federal government fails to provide Americans with reproductive health information they need. Here’s a better approach

Opinion: The federal government fails to provide Americ...

Dec 15, 2023

MiNA and BioMarin partner to speed development of RNAa therapies

MiNA and BioMarin partner to speed development of RNAa ...

Apr 26, 2023

Here’s why obesity grew so quickly worldwide, and where that’s starting to change

Here’s why obesity grew so quickly worldwide, and where...

Jun 8, 2023